Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells

British Journal of Pharmacology

Volumn 124, Issue 8, 1998, Pages 1751-1759

  Passaquin, Anne Catherine ^a   Lhote, Philippe ^a   Rüegg, Urs T ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Antioxidant; C2C12 cells; Calcium; Duchenne muscular dystrophy; Glucocorticoid; Lazaroid; Manoalide; Mifepristone; Oxidant; Skeletal muscle

Indexed keywords

2 [[4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL]METHYL] 3,4 DIHYDRO 2,5,7,8 TETRAMETHYL 2H 1 BENZOPYRAN 6 OL; 21 [4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL]PREGNA 1,4,9(11) TRIENE 3,20 DIONE; ALPHA TOCOPHEROL; ASCORBIC ACID; BUTYLATED HYDROXYANISOLE; BUTYLCRESOL; CALCIUM ION; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MANOALIDE; METHYLPREDNISOLONE; MIFEPRISTONE; NORDIHYDROGUAIARETIC ACID;

ARTICLE; CALCIUM TRANSPORT; MUSCLE CELL; PRIORITY JOURNAL;

ANNEXINS; ANTIOXIDANTS; CALCIUM CHANNEL BLOCKERS; CELL LINE; HORMONE ANTAGONISTS; HUMANS; MUSCLE, SKELETAL; OXIDANTS; PHOSPHOLIPASES A; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, GLUCOCORTICOID; STEROIDS; TIME FACTORS;

EID: 0031817490     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702036     Document Type: Article

References (45)

1. AGARWAI, M.K. (1996). The antiglucocorticoid action of mifepristone. Pharmacol. & Therap., 70, 183-213.
2. ANGELINI, C., PEGORARO, E., TURELLA, E., INTINO, M.T., PINI, A. & COSTA, C. (1994). Deflazacort in Duchenne muscular dystrophy study of long-term effect. Muscle & Nerve. 17, 386-391.
3. BALLARD, P.L., CARTER, J.P., GRAHAM, B.S. & BAXTER, J.D. (1975). A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man. J. Clin. Endocrinol. Metab., 41, 290-304.
4. BAULIEU, E.E. (1989). Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor. Science. 245, 1351-1357.
5. BEHL, C., TRAPP, T., SKUTELLA, T. & HOLSBOER, F. (1997). Protection against oxidative stress-induced neuronal cell death a novel role for RU486. Eur. J. Neurosci., 9, 912-920.
6. BRAUN, S., TRANCHANT, C., VILQUIN, J.-T., LABOURET, P., WARTER, J.-M. & POINDRON, P. (1989). Stimulating effects of prednisolone on acetylcholine receptor expression and myogenesis in primary cultures of newborn rat muscle cells. J. Neurol. Sci., 92, 119-131.
7. CASTRO, G.J. & BHATNAGAR, A. (1993). Effects of extracellular ions and modulators of calcium transport on survival of tert-butyl hydroperoxyde exposed cardiac myocytes. Cardiovasc. Res., 27, 1873-1881.
8. DIAMOND, S.L., SACHS, F. & SIGURDSON, W.J. (1994). Mechanically induced calcium mobilization in cultured endothelial cells is dependent on actin and phospholipase. Arteriosclerosis & Thrombosis. 14, 2000-2006.
9. DUBOWITZ, V. (1996). 47th ENMC international workshop: Treatment of muscular dystrophy 13 15 December 1996, Naarde, the Netherlands. Neuromuscular Disorders. 7, 261-267.
10. DUNN, J.F. & RADDA, G.K. (1991). Total ion content of skeletal and cardiac muscle in the mdx mouse dystrophy: calcium is elevated at all ages. J. Neurol. Sci., 103, 226-231.
11. FENICHEL, G.M., BROOKE, M.H., GRIGGS, R.C., MENDELL, J.R., MILLER, J.P. MOXLEY, R.T., PARK, J.H., PROVINE, M.A., FLORENCE, J. KAISER, K.K., KING, W.M., PANDYA, S., ROBISON, J. & SIGNORE, L. (1988). Clinical investigation in Duchenne muscular dystrophy: penicillamine and vitamin E. Muscle & Nerve. 11, 1164-1168.
12. FENICHEL, G.M., FLORENCE, J.M., PESTROMK, A., MENDELL, J.R., MOXLEY, R.T., GRIGGS, R.C., BROOKE, M.H., MILLER, J.P., ROBISON, J., KING, W., SIGNORE, L., PANDYA, S., SCHIERBRECKER, J. & WILSON, B. (1991). Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology, 41, 1874-1877.
13. FONG, P., TURNER, P., DENETCLAW, W. & STEINHARDT, R. (1990). Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin. Science, 250, 673-676.
14. FRANCO, A. Jr & LANSMAN, J.B. (1990). Calcium entry through stretch-inactivated ion channels in mdx myotubes. Nature, 344, 670-673.
15. FLOWER, R.D. & ROTHWELL, N.J. (1994). Lipocortin-1: cellular mechanisms and clinical relevance. Trends Pharmacol. Sci. 15, 71-76.
16. HALL, E.D. (1993). Neuroprotective actions of glucocorticoid and nonglucocorticoid steroids in acute neuronal injury. Cell. Mol. Neurobiol., 13, 415-432.
17. HAYCOCK, J.W., MACNEIL, S., JONES, P., HARRIS, J.B. & MANTLE, D. (1996). Oxidative damage to muscle protein in Duchenne muscular dystrophy. Neuroreport, 8, 357-361.
18. HOFFMAN, E.P. & SCHWARTZ, L. (1991). Dystrophin and disease. Mol. Asp. Med., 12, 175-194.
19. JACKSON, M.J. & O'FARRELL, S.O. (1993). Free radicals and muscle damage. Br. Med. Bull., 49, 630-641.
20. KAHN, M.A. (1993). Corticosteroid therapy in Duchenne muscular dystrophy. J. Neurol. Sci., 120, 8-14.
21. KAPLAN, I., BLAKELY, B.T., PAVLATH, G.K., TRAVIS, M. & BLAU, H.M. (1990). Steroids induce acetylcholine receptors on cultured human muscle: implications for Myasthenia gravis. Proc. Natl. Acad. Sci. U.S.A., 87, 8100-8104.
22. KOENIG, M., HOFFMAN, E.P., BERTELSON, C.J., MONACO, A.P., FEENER, C. & KUNKEL, L.M. (1987). Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 50, 509-517.
23. KRALLI, A. & YAMAMOTO, K.R. (1996). An FK506-sensitive transporter selectively decreases intracellular levels and potencies of steroid hormones. J. Biol. Chem., 271, 17152-17156.
24. LEIJENDEKKER W.J., PASSAQUIN A.C. & RÜEGG U.T. (1996). Regulation of cytosolic calcium under stress conditions in skeletal muscle cells from mdx mice. Br. J. Pharmacol., 118, 611-616.
25. MADHAVAN, R. & JARRETT, H.W. (1994). Calmodulin-activated phosphorylation of dystrophin. Biochemistry, 33, 5797-5804.
26. +) ATP-ase. Biochem. Biophys. Res. Commun., 66, 115-122.
27. McEWAN, I.J., WRIGHT, A.P. & GUSTAFSSON, J.A. (1997). Mechanism of gene expression by the glucocorticoid receptor: role of protein-protein interactions. Bioessays. 19, 153-160.
28. MENDELL, J.R., MOXLEY, R.T., GRIGGS, R.C., BROOKE, M.H., MILLER, J.P., MANDEL, S., ROBINSON, J., ARFKEN, C. & GILDER, B. (1989). Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N. Eng. J. Med., 320, 1592-1597.
29. METZINGER, L., PASSAQUIN, A.C., LEIJENDEKKER, W.J., POINDRON, P. & RÜEGG, U.T. (1995). Modulation by prednisolone of calcium handling in skeletal muscle cells. Br. J. Pharmacol., 116, 2811-2816.
30. METZINGER, L., PASSAQUIN, A.C., VERNIER, A., THIRIET, N., WARTER, J.-M. & POINDRON, P. (1994). Lazaroids enhance skeletal myogenesis in primary cultures of dystrophin-deficient mdx mice. J. Neurol. Sci., 126, 138-145.
31. METZINGER, L., PASSAQUIN, A.C., WARTER, J.-M. & POINDRON, P. (1993). α-methylprednisolone promotes skeletal myogenesis in dystrophin-deficient and control mouse cultures. Neurosci. Lett. 155, 171-174.
32. NUROWSKA, E. & RUZZIER, F. (1996). Corticosterone modifies the murine muscle acetylcholine receptor channel kinetics. Neuroreport, 8, 77-80.
33. ORCHINIK, M., MURRAY, T.F. & MOORE, F.L. (1991). A corticosteroid receptor in neuronal membrane. Science. 252, 1848-1851.
34. PASQUINI, F., GUERIN, C., BLAKE, D., DAVIES, K., KARPATI, G. & HOLLAND, P. (1995). The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells. Neuromusc. Disord., 5, 105-114.
35. PASSAQUIN, A.C., METZINGER L., LEGER, J.J., G., WARTER, J.-M. & POINDRON, P. (1993). Prednisolone enhances myogenesis and dystrophin-related protein in skeletal muscle cells from mdx mouse. J. Neurosci. Res., 35, 363-372.
36. PETROF, B.J., SHRAGER, J.B., STEDMAN, H.H., KELLY, A.M. & SWEENEY, H.L. (1993). Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA, 90, 3710-3714.
37. SICINSKI, P., GENG, Y., RYDER-COOK, A.S., BARNARD, E.A., DARLISON, M.G. & BARNARD, P.J. (1989). The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 244, 1578-1580.
38. SPITZ, I.M., CROXATTO, H.B. & ROBBINS, A. (1996). Antiprogestins: Mechanism of action and contraceptive potential. Ann. Rev. Pharmacol. Toxicol., 36, 47-81.
39. SUNADA, Y. & CAMPBELL, K.P. (1995). Dystrophin-glycoprotein complex: molecular organization and critical roles in skeletal muscle. Curr. Op. Neurol., 8, 379-384.
40. TINSLEY, J.M., POTTER, A.C., PHELPS, S.R., FISHER, R., TRICKETT, J.I. & DAVIES, K.E. (1996). Amelioration of the dystrophic phenotype of mice using a truncated utrophin transgene. Nature, 384, 349-353.
41. TURNER, P.R., SCHULTZ, R., GANGULY, B. & STEINHARDT, R. (1993). Proteolysis results in altered leak channel kinetics and elevated free calcium in mdx muscle. J. Membrane Biol., 133, 243-251.
42. TURNER, P.R., WESTWOOD, T., REGEN, C.M. & STEINHARDT, R. (1988). Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature, 335, 735-738.
43. UHLER, T.A., FRIM, D.M., PAKZABAN, P. & ISACSON, O. (1994). The effect of mega doses of methylprednisolone and U-78517F on toxicity mediated by glutamate receptors in the rat neostriatum. Neurosurgery, 34, 122-127.
44. YAFFE, D. & SAXEL, O. (1977). Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature, 270, 725-727.
45. ZUBRZYCKA-GAARN, E.E., BULMAN, D.E., KARPATI, G. BURGHES, A.H.M., BELFALL, B., KLAMUT, H.J., TALBOT, J. & WORTON, R.G. (1988). The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature, 333, 466-469.